Tris Pharma has a rich history of engaging in successful partnerships across multiple strategies. We are actively seeking innovative CNS therapeutics that we can further develop and commercialize. We also focus on out-licensing our internal clinical and commercial-stage programs for ex-U.S. territories, and we work closely with partners to create best-in-class medicines by applying our drug delivery platforms (LiquiXR®, RaftWorksTM and more) to their programs.
Learn more about Tris’ technologies here.
Kye Pharma
Kye Pharma was Tris Pharma’s first ex-U.S. partner for our approved ADHD portfolio, bringing our ADHD medicines to patients in Canada.
Neuraxpharm
Neuraxpharm licensed the rights to develop and commercialize our FDA-approved Quillivant XR and Quillichew ER in 40+ European countries.
Pediatrix Therapeutics
We partnered with Pediatrix Therapeutics to bring our FDA-approved ADHD medicines, as well as an investigational ADHD therapy, to patients in China.
Perrigo Co.
Perrigo has a been a commercial partner since 2012.
Perigon Pharmacy
We partnered with Perigon Pharmacy 360 to enhance accessibility, affordability and adherence via a digital pharmacy for patients.
Braingaze
We licensed the rights to develop and commercialize Braingaze’s first-in-class, AI-enhanced digital ADHD diagnostic platform in the United States and Canada.
Interested in collaborating with Tris? Whether it’s a program you want to out-license, or an ex-U.S. or Tris-technology partnership, we’d love to hear from you!
This form is not intended for use in reporting adverse events related to Tris medicines. You may report such events by calling 1-732-940-0358 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch, where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense or use. Visit MedWatch or call 1-800-FDA-1088.